Valink Therapeutics vs IBM
Side-by-side comparison of AI visibility scores, market position, and capabilities
Clinical-stage ADC biotech with ValiLinker site-specific conjugation technology; VLT-03 in Phase I for solid tumors and VLT-01 for brain metastases with $20.5M raised.
About
Valink Therapeutics is a clinical-stage biotechnology company developing antibody-drug conjugates (ADCs) for solid tumors using its proprietary ValiLinker technology — a site-specific conjugation platform that precisely attaches cytotoxic payloads to antibodies at defined positions, improving ADC stability, homogeneity, and therapeutic index compared to conventional random-conjugation approaches. Founded in 2020 and headquartered in Houston, Texas, Valink raised $20.5 million total including an $11.8 million Pre-Series A in October 2025 to advance its pipeline into clinical trials.\n\nValink's pipeline centers on VLT-03 (targeting solid tumors in Phase I trials) and VLT-01 (targeting solid tumors with brain metastases, addressing the significant unmet need in CNS-penetrating oncology therapeutics). The ValiLinker conjugation technology enables precise drug-to-antibody ratios and reduces off-target toxicity that has historically limited ADC tolerability — the platform differentiates Valink from earlier ADC developers by addressing the conjugation chemistry precision that drives therapeutic index improvements in this modality.\n\nIn 2025, Valink competes in the ADC space with Seagen (acquired by Pfizer), ImmunoGen (acquired by AbbVie), Daiichi Sankyo (partnered with AstraZeneca), and numerous clinical-stage biotech ADC developers. ADC development has become one of the most active areas in oncology after the commercial success of Enhertu (trastuzumab deruxtecan) demonstrated the potential of the modality. Valink's site-specific conjugation differentiation targets the technical limitations of first-generation ADCs that created toxicity issues. The 2025-2026 strategy focuses on Phase I dose escalation for VLT-03, building clinical proof-of-concept for the ValiLinker platform, and positioning for partnership or licensing discussions with large pharma.
Armonk NY hybrid cloud and enterprise AI (NYSE: IBM) at $62.8B revenue; $6B+ generative AI bookings, record $12.7B free cash flow 2024, DataStax acquisition for watsonx vector database competing with Microsoft Azure for enterprise AI.
About
International Business Machines Corporation (IBM) is an Armonk, New York-based global technology and consulting company — publicly traded on the New York Stock Exchange (NYSE: IBM) as an S&P 500 component — providing hybrid cloud infrastructure, artificial intelligence software, and enterprise IT consulting through approximately 270,300 employees in 170 countries with $62.8 billion in annual revenue. Founded on June 16, 1911, as Computing-Tabulating-Recording Company through a merger orchestrated by financier Charles Ranlett Flint, renamed IBM in 1924 under Thomas Watson Sr., IBM has undergone multiple strategic transformations over its 110+ year history: building the System/360 mainframe platform (1964), launching the IBM PC (1981), selling the PC division to Lenovo (2005, $1.75B), and completing the $34 billion Red Hat acquisition (2019) that repositioned IBM as a hybrid cloud platform company. CEO Arvind Krishna (appointed April 2020) has focused IBM's strategy on three areas: hybrid cloud (powered by Red Hat OpenShift, the enterprise Kubernetes platform), AI (the watsonx platform for enterprise AI model development and deployment), and enterprise consulting. Under Krishna, IBM recorded $12.7 billion in free cash flow in 2024 (a company record), surpassed $6 billion in generative AI bookings since June 2023, and saw the stock price double — trading at all-time highs through 2024-2025. IBM announced the DataStax acquisition in 2025 to deepen watsonx's data layer with AstraDB (vector database for AI applications), DataStax Enterprise (Apache Cassandra), and Langflow (low-code AI agent development).
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.